These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 26796639)

  • 21. An assessment of iloperidone for the treatment of schizophrenia.
    Jain KK
    Expert Opin Investig Drugs; 2000 Dec; 9(12):2935-43. PubMed ID: 11093363
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials.
    Weiden PJ; Cutler AJ; Polymeropoulos MH; Wolfgang CD
    J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S12-9. PubMed ID: 18334908
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A thorough QTc study of 3 doses of iloperidone including metabolic inhibition via CYP2D6 and/or CYP3A4 and a comparison to quetiapine and ziprasidone.
    Potkin SG; Preskorn S; Hochfeld M; Meng X
    J Clin Psychopharmacol; 2013 Feb; 33(1):3-10. PubMed ID: 23277250
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies.
    Potkin SG; Litman RE; Torres R; Wolfgang CD
    J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S4-11. PubMed ID: 18334911
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ex vivo studies with iloperidone (HP 873), a potential atypical antipsychotic with dopamine D2/5-hydroxytryptamine2 receptor antagonist activity.
    Szczepanik AM; Brougham LR; Roehr JE; Conway PG; Ellis DB; Wilmot CA
    J Pharmacol Exp Ther; 1996 Aug; 278(2):913-20. PubMed ID: 8768747
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modulating sensorimotor gating in healthy volunteers: the effects of desipramine and haloperidol.
    Oranje B; Kahn RS; Kemner C; Verbaten MN
    Psychiatry Res; 2004 Jul; 127(3):195-205. PubMed ID: 15296819
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Iloperidone for the management of adults with schizophrenia.
    Crabtree BL; Montgomery J
    Clin Ther; 2011 Mar; 33(3):330-45. PubMed ID: 21600386
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia.
    Leucht S; Crippa A; Siafis S; Patel MX; Orsini N; Davis JM
    Am J Psychiatry; 2020 Apr; 177(4):342-353. PubMed ID: 31838873
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia.
    Cutler AJ; Kalali AH; Weiden PJ; Hamilton J; Wolfgang CD
    J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S20-8. PubMed ID: 18334909
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Iloperidone for the treatment of schizophrenia.
    Marino J; Caballero J
    Ann Pharmacother; 2010 May; 44(5):863-70. PubMed ID: 20388862
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Switching patients from clozapine to risperidone therapy.
    Zimbroff DL
    Am J Psychiatry; 1995 Jul; 152(7):1102. PubMed ID: 7540802
    [No Abstract]   [Full Text] [Related]  

  • 32. Iloperidone for the treatment of schizophrenia.
    Bishop JR; Bishop DL
    Drugs Today (Barc); 2010 Aug; 46(8):567-79. PubMed ID: 20830317
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Effect of Chronic Iloperidone Treatment on Cytochrome P450 Expression and Activity in the Rat Liver: Involvement of Neuroendocrine Mechanisms.
    Danek PJ; Kuban W; Daniel WA
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445153
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alcohol drinking of alcohol-preferring AA rats is differentially affected by clozapine and olanzapine.
    Ingman K; Korpi ER
    Eur J Pharmacol; 2006 Mar; 534(1-3):133-40. PubMed ID: 16480711
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Iloperidone reduces sensorimotor gating deficits in pharmacological models, but not a developmental model, of disrupted prepulse inhibition in rats.
    Barr AM; Powell SB; Markou A; Geyer MA
    Neuropharmacology; 2006 Sep; 51(3):457-65. PubMed ID: 16762376
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Idazoxan and 8-OH-DPAT modify the behavioral effects induced by either NA, or 5-HT, or dual NA/5-HT reuptake inhibition in the rat forced swimming test.
    Rénéric JP; Bouvard M; Stinus L
    Neuropsychopharmacology; 2001 Apr; 24(4):379-90. PubMed ID: 11182533
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The guinea pig forced swim test as a new behavioral despair model to characterize potential antidepressants.
    Wicke KM; Rex A; Jongen-Relo A; Groth I; Gross G
    Psychopharmacology (Berl); 2007 Nov; 195(1):95-102. PubMed ID: 17646967
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advances in atypical antipsychotics for the treatment of schizophrenia: new formulations and new agents.
    Kelleher JP; Centorrino F; Albert MJ; Baldessarini RJ
    CNS Drugs; 2002; 16(4):249-61. PubMed ID: 11945108
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Iloperidone: a clinical overview.
    Citrome L
    J Clin Psychiatry; 2011; 72 Suppl 1():19-23. PubMed ID: 22217439
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined alpha 2-adrenergic/D2 dopamine receptor blockade fails to reproduce the ability of clozapine to reverse phencyclidine-induced deficits in prepulse inhibition of startle.
    Ballmaier M; Zoli M; Mazzoncini R; Gennarelli M; Spano F
    Psychopharmacology (Berl); 2001 Dec; 159(1):105-10. PubMed ID: 11797077
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.